Knight Therapeutics Inc KHTRF

Primary Symbol: T.GUD

Healthcare

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > 57.08 % shares held In tight hands- sharecount shrinks

<< Previous

Bullboard Posts

Next >>

Comment by longrun86on Oct 08, 2023 11:15am

154 Views

Post# 35675155

RE:57.08 % shares held In tight hands- sharecount shrinks

It's always nicer to be in business with "owners" of the company compared to fair-weather "renters".

Ultimately though, the return profile based on the capital invested is too low and needs to get fixed. The competitive issues don't get fixed overnight, and the scale also takes a while to reach. Nobody said it was an easy industry!

I am looking forward to meaningful updates from Management over the coming quarters about profitability!

LR

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec